ValuEngine Lowers OraSure Technologies (OSUR) to Sell

ValuEngine lowered shares of OraSure Technologies (NASDAQ:OSUR) from a hold rating to a sell rating in a research report released on Monday, February 4th.

Several other research firms have also recently issued reports on OSUR. BidaskClub upgraded shares of OraSure Technologies from a strong sell rating to a sell rating in a report on Wednesday, October 24th. Raymond James reiterated a mkt perform rating on shares of OraSure Technologies in a report on Tuesday, October 23rd. Zacks Investment Research cut shares of OraSure Technologies from a strong-buy rating to a hold rating in a report on Wednesday, November 7th. Finally, TheStreet lowered shares of OraSure Technologies from a b rating to a c+ rating in a research note on Thursday, November 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company. OraSure Technologies has an average rating of Hold and an average target price of $16.50.

Shares of NASDAQ:OSUR opened at $11.12 on Monday. OraSure Technologies has a fifty-two week low of $9.15 and a fifty-two week high of $18.71. The stock has a market cap of $710.80 million, a P/E ratio of 22.24, a price-to-earnings-growth ratio of 2.38 and a beta of 1.42.

OraSure Technologies (NASDAQ:OSUR) last posted its earnings results on Wednesday, February 6th. The medical instruments supplier reported $0.20 EPS for the quarter, topping the consensus estimate of $0.11 by $0.09. The firm had revenue of $50.25 million during the quarter, compared to analysts’ expectations of $47.77 million. OraSure Technologies had a net margin of 11.22% and a return on equity of 8.45%. OraSure Technologies’s quarterly revenue was down 3.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.12 EPS. On average, research analysts expect that OraSure Technologies will post 0.39 earnings per share for the current year.

Several large investors have recently modified their holdings of the stock. BlackRock Inc. lifted its position in shares of OraSure Technologies by 5.9% in the 3rd quarter. BlackRock Inc. now owns 8,979,357 shares of the medical instruments supplier’s stock valued at $138,732,000 after acquiring an additional 498,527 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of OraSure Technologies by 1.5% in the 3rd quarter. Vanguard Group Inc. now owns 3,576,389 shares of the medical instruments supplier’s stock valued at $55,256,000 after acquiring an additional 53,671 shares in the last quarter. Vanguard Group Inc lifted its position in shares of OraSure Technologies by 1.5% in the 3rd quarter. Vanguard Group Inc now owns 3,576,389 shares of the medical instruments supplier’s stock valued at $55,256,000 after acquiring an additional 53,671 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of OraSure Technologies by 1.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,918,182 shares of the medical instruments supplier’s stock valued at $34,084,000 after acquiring an additional 31,216 shares in the last quarter. Finally, American Capital Management Inc. lifted its position in shares of OraSure Technologies by 275.5% in the 4th quarter. American Capital Management Inc. now owns 1,720,032 shares of the medical instruments supplier’s stock valued at $20,090,000 after acquiring an additional 1,262,015 shares in the last quarter. Institutional investors and hedge funds own 92.51% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Recommended Story: Why Net Income is Important to Investors

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply